Top Markets
#1 Helium Helium +47.34%
#2 TENDIES TENDIES +43.82%
#3 Pons Pons +38.81%
#4 UnifAI Network UnifAI Network +18.28%
#5 Seeker Seeker +16.90%
#6 Songbird Songbird +15.77%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +10.42%
#8 DAPPOS DAPPOS +10.15%
#9 OSK OSK +10.10%
#10 Bounce Bounce +9.81%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Philogen S.p.A. Philogen S.p.A.

Philogen S.p.A.

PHIL
Rank in Stocks #10685
Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic... Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.
Share Price
$27.76
Last synced: 2026-08-28
Market Cap
$801.60M
Change (1 day)
0.21%
Change (1 year)
0.65%
Country
IT
Trade Philogen S.p.A. (PHIL)

Category

Healthcare
Number of shares outstanding for Philogen S.p.A. (PHIL)
Number of shares outstanding as of August 2026: 0
According to Philogen S.p.A. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Philogen S.p.A. (PHIL) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH